/

Empresas

Ba

No verificado

Bayer

Sobre qué escribimos

BiotecnologíaFarmacéuticaIndustriaMedicina - VariosSalud

186 Comunicados de prensa

Ver todos los comunicados de prensa

10/11/2026

Bayer’s SUNHARBO® (asundexian), 50 mg tablets, the First and Only Factor XIa Inhibitor, Approved by the U.S. FDA to Reduce the Risk of Stroke in Adults With Recent Non-Cardioembolic Ischemic Stroke or High-Risk Transient Ischemic Attack...

Fuente

Editor

1.00

0

06/11/2026

First U.S. Convintro™ Herbicide Delivery Launches a New Weed-Control Option for Corn and Soybean Growers

Fuente

Editor

1.00

0

04/11/2026

Bayer and America’s Grow-a-Row Continue Partnership to Fight Food Insecurity

Fuente

Editor

1.00

0

03/11/2026

Eventos

Ferias y Congresos

Industria

Ciencia

Higiene alimentaria

Salud

Medicina - Varios

Cardiología

Biotecnología

Farmacéutica

Bayer to Present New Cardiovascular, Kidney and Stroke Data at the 2026 American Heart Association (AHA) Scientific Sessions

Fuente

Editor

1.00

0

26/10/2026

Salud

Ir de compras

Medicina - Varios

Farmacéutica

Biotecnología

Industria

Bayer Shares New Post Hoc Analysis Of Self-Reported Sleep-Related Outcomes with Lynkuet® (elinzanetant) in Women with Moderate to Severe Vasomotor Symptoms at the Menopause Society Annual Meeting

Fuente

Editor

1.00

0

24/10/2026

Oncología

Salud

Medicina - Varios

Ciencia

Farmacéutica

Eventos

ESMO 2026: NUBEQA® (darolutamide) Plus ADT and Radiation Therapy Reduces Risk of Metastasis or Death by 58% in Prostate Cancer Patients at High Risk of Recurrence

Fuente

Editor

1.00

0

08/10/2026

Ferias y Congresos

Eventos

Industria

Salud

Sanidad

Farmacéutica

Cardiología

Biotecnología

Bayer to Present New Cardiac Amyloidosis and Heart Failure Data at the Heart Failure Society of America (HFSA) Annual Scientific Meeting

Fuente

Editor

1.00

0

08/10/2026

Actress and Menopause Advocate Melissa Joan Hart Partners with Bayer to Raise Awareness about Lynkuet® (elinzanetant), a Prescription Treatment for Moderate to Severe Hot Flashes due to Menopause

Fuente

Editor

1.00

0

08/10/2026

Industria

Higiene alimentaria

Salud

Medicina - Varios

Farmacéutica

Biotecnología

U.S. FDA Accepts Bayer’s Supplemental New Drug Application for KERENDIA® (finerenone) to Treat Adults with Chronic Kidney Disease (CKD) Without Diabetes

Fuente

Editor

1.00

0

02/10/2026

Bayer to Invest 2.2 Billion U.S. Dollars in a New Manufacturing Site in the United States

Fuente

Editor

1.00

0

Seguidores

0

Compatibilidad

0